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1. Introduction 
In humans, female’s humoral and cellular immunity are actually stronger than men 
(Nalbandian & Kovats, 2005) and present a higher antibody serum titration than men 
(Giron-Gonzalez et al., 2000) which could logically and possibly explain their gender 
predisposition and susceptibility to autoimmunity. Holding an autoimmune disease and 
becoming pregnant is a serious matter for a woman and knowledge of the course of the 
condition during pregnancy is essential. Relational variations exist between types of 
autoimmuny during pregnancy and consequently proper advices from physicians are 
provided accordingly. In Systemic lupus erythematosus, all advices provided to the patients 
are meant to dissuade women from getting pregnant while being in a relapse stage of the 
disease and better wait for the end of the flare pathological course.  As for Rheumatoid 
arthritis and multiple sclerosis, no real dangers are encountered while being pregnant and 
while the disease symptoms are expressed it still does not present life threatening risks to 
the gestation. In Myasthenia gravis, during gestation the risks are variable and retrospective 
studies show increase complications. 
Logically, the baby carrying semi-allogenic antigens should prompt an autoimmune 
reaction from the mother. However a plethora of tolerance measures is put into action by 
both the mother and the foetus.  Pre implantation immunological events are in place to best 
prepare the nidation of the foetus into the mother endometrium. There is large paucity of 
published scientific research studies that have attempted to understand the entire 
pregnancy immune profile due to low power studies, limiting longitudinal samplings and 
narrow immune component analysis. However, a recent study has shown a Th1 toTh2 shift 
with increase interleukin 10 synthesis and a decrease responses to pro-inflammatory 
cytokines such as TNFα, Il-1β and Il-6 during pregnancy (Denney et al., 2011). 
Immunological adaptations occur early in gestation and are mediated by the uterine 
epithelium including the fallopian tube secretion of granulocyte macrophage colony 
stimulating factors (GM-CSF) (Rosendaal, 1975). In addition, the trophoblast that is derived 
from the fertilized egg secretes GM-CSF to prepare best for the next step of implantation 
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and formation of the placenta (Burgess et al., 1977). Post implantation, the placenta is 
formed to accommodate, protect and feed with key nutrients the growing foetus. The 
placenta is formed of different layers with the basal plate or deciduas basalis, a structure in 
direct contact with the endometrium, the intermediate layer being the lacunar system and 
finally the chorionic plate made of two leaflets, the chorionic plate and the amniotic plate. 
Interestingly, the content of the decidua is composed of different key factors aiming at 
inducing tolerance and include cells such as maternal Natural killers and regulatory T-cells. 
Natural killer cells are secreting lots of cytokines with immunoregulation purposes and are 
non cytotoxic (Chantakru et al., 2002). As for the regulatory T-cells, data showed that human 
chorionic gonadotropin hormone is responsible for the attraction of such cells in the 
placenta (Schumacher et al., 2009). It has also been proved that Treg are key determinants in 
murine pregnancy (Zenclussen et al., 2005) with possibly the mediation of interleukin 10 
(Taylor et al., 2006 & Akdis et al., 2001). The relative proportion of immune cells found in 
the deciduas are as follows, 70% of natural killers (Moffet et al., 2004), 20% of macrophages 
(Lessin et al., 1988), around 2% of T lymphocytes (Lessin et al., 1988), 1% of dendritic cells 
(Gardner et al., 2003) and very minute B cell lymphocytes (Veenstra Van Nieuwenhoven et 
al., 2003).  In addition, regulatory proteins decreasing complement action are found in the 
decidua basalis more precisely on the syncyciotrophoblast T-cells along with cellular 
membranar Fas ligands and MHC molecules. MHC molecules consist of class III MHC 
molecules but lack of particular HLAI and HLA II molecules including HLA-A and -B as 
well as HLA-DP, -DQ and –DR is noticed (Landek-Salgado et al., 2010). Interestingly the 
placenta is maintaining a tied tolerance status mediated by each of its functional molecular 
and cellular components playing a major role in this process. Mostly, any activated T-cells 
that would reach this mother-foetus interface border would be bound to Fas ligand on their 
Fas receptor condemning them to enter apoptosis (Pongcharoen et al., 2004). This apoptotic 
process is mediated by Fas pathway through the activation of the death induce signaling 
complex that ultimately activates the caspase apoptotic cascade. More importantly, 
regulatory T-cells accumulating in the decidua during pregnancy, dampen any pro-
inflammatory that harm the foetus (Tilburgs et al., 2008).  
Along with this immunosuppressive function, an immune tolerance is strongly put in place. 
Transient gestational lowering reactivity is set to prevent potent T-cells from reacting 
against the semi-allogenic foetus and previously demonstrated in animal studies (Tafuri et 
al., 1995). Immuno tolerance features that directly play roles on pro-inflammatory immune 
cells are relying on particular cells called T regulatory cells or Tregs (Kuniyasu et al., 2000). 
Tregs can be Th4 lymphocytes or T8 lymphocytes and are mostly found to act as 
immunomodulators in regions of inflammation (Gavin et al., 2002). The action is mediated 
by contact inhibition of non Treg cells such include subsets of T 4 and T8 lymphocytic cells. 
Specific markers are differentiating these subsets from regulatory to non regulatory effective 
T-cells (Teff) and include CD25 markers (α chain of IL-2 receptor) with the so called CD4+ 
CD25+ and CD8+CD25+ cells. Additional markers are also found in Tregs such as FoxP3+ 
marker, a repressor activator of activated T-cells such as CD4+CD25+FoxP3+ Treg cells or 
Cd8+ CD25+ CDFoxP3+ Treg cells. Another Treg marker is CXCR3+ seen in CD8+ CXCR3+ 
Treg cells. The Treg mediation in tolerance restoration can be undertaken through different 
mechanisms. Tolerance could be undertaken by contact interaction such as Fas- Fas ligand 
interaction dictating an apoptotic faith to the Teff cells (Watanabe et al, 2002). The other way 
Tregs are promoting tolerance to Teff cells is to inhibit Teff cytokine synthesis and 
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subsequently their Teff cytolytic activation as well as diminishing their proliferation 
(Duthoit et al., 2005). Teff cells can be CD8+ or CD4+ cells with the latter being classified 
into two types, TH1 and TH2 both differing in action as pro-inflammatory and anti-
inflammatory actions respectively. Briefly, the Th1 activation pathway consists in interferon 
γ inducing activation of its cell surface receptor on T cells and subsequent intracellular 
cascade activation. Such cascade leads to the activation of the transcription factor T-bet 
which function is to bind DNA responsive elements of genes within the nucleus. The main 
responsive elements controlled and activated belong to the genes interferon γ and IL-12 
receptor β2 chain. Upon activation, further expression of these genes is undertaken and IL-
12 receptor becomes widely available at higher amounts in the cellular T-cell membranar 
surface and therefore can be prompted to activation due to the presence of local IL-12 
cytokine. IL-12 receptor actiavtion induces a second cascade that is Stat 4 dependent, with 
the ultimate goal to produce furthermore T-bet transcription factor. Relation between Tregs 
and pro-inflammatory TH1 and CD8+ T-cells demonstrate an interesting phenomenon that 
is build around the competition for Interleukin 2 binding. In sites of inflammation, binding 
of IL-2 by Tregs diminishes the availability of IL-2 to Teffs and therefore limiting their 
growth, function and even at early stage turning Teffs to be anergic towards antigens 
(Piccirillo et al., 2001). Briefly, T-cells are activated through the contact of antigen with T-cell 
receptor under the restriction of MHC class molecules. Such binding activates p56lck 
tyrosine kinase with subsequent downstream phosphorylation of proteins and activation of 
phospholipase C. Such phospholipase generates from phosphatidyl inositol diphosphate, 
two compounds; the diacyl glycerol and inositol tri-phosphate, IP3.  The endoplasmic 
reticulum IP3 receptor is therefore activated with release of calcium in the cytosol. Such 
Ca2++ induces a membranar activation of the cell membrane calcium release activated 
calcium channel named CRAC and subsequently increases highly the intracellular Ca2++ 
concentration. High levels of Ca2++ activate caclineurin, a phosphatase that 
dephosphorylates the transcriptional factor NFAT (nuclear factor of activated T-cells). Such 
dephosphorylated NFAT translocates into the nucleus to reach responsive elements of Il-2, 
AP1 and NFKB enabling their expression and future function. Beside the roles of Tregs as 
pro-apoptotic cytolytic Teff cells inducers and Teff cells expansion inhibitors, Tregs are 
capable to modulate the  inflammatory ‘soup’ and pattern observed in inflammation sites. 
Such action of Tregs is mediated by their synthesis and secretion of both TGFβ and 
interleukin 10. A higher content of Il-10 is maintained due to Teffs response to TGFβ action 
and secondly by Il-10 action on dictating Teffs to respond with higher affinity to TGFβ. In 
addition, the constant increase of progesterone in gestation, which is peaking at the third 
trimester, is responsible for the activation of particular subsets of T-cells called γδ T-cells. 
Upon binding to its receptor, progesterone activates γδ T-cells to secrete Il-10 and 
progesterone induced blocking factor (PIBF) that result in the inhibition of natural killer 
cells (Barakonyi et al., 1999). In addition, these cells synthesise TGFβ that enhances the 
mother’s T-cell tolerance for the foetus (Mincheva-Nilsson et al., 1992). 
2. Autoimmunity and pregnancy 
Women are more prevalent to autoimmunity and 3 to 5% will be affected by such disorders. 
During pregnancy, clinical course of several autoimmune disease are expressed with 
variable degrees. Some range from higher remission of signs and symptoms while others are 
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being increased in exacerbations. These influences observed in Pregnancy denote a complex 
interaction between the pathophysiological course of the disease and the physiological 
adaptations during pregnancy.  Presence of a wide spectrum of auto-antibodies correlates 
with the parturient pathophysiological course. In some autoimmune diseases, the risk of 
transient neonatal illness could be observed and can range from low risk as in myasthenia 
gravis to relatively higher as in Lupus. Self tolerance mechanisms at the cellular and genetic 
levels are modulated during pregnancy by these autoimmune diseases. Such modulation 
might reside at different levels and include, allelic variation with the HLA loci and 
expression, physiological adaptations during pregnancy  (hormones) and alteration towards 
the host immunity or the foetal antigens (paternal HLAs), cytokine profile during 
pregnancy, HLA from foetus (HLA-G), structural interface integrity between foetus and 
mother, status of  intrinsic and extrinsic controls preventing-autoimmunity. 
We aim in this review at discussing the immunological events that surround pregnancy and 
autoimmunity especially by focusing on Systemic lupus erythematosus, Rheumatoid 
arthritis, Myasthenia gravis and Multiple sclerosis. 
2.1 Systemic Lupus Erythematosus 
2.1.1 Pathophysiology of SLE 
Systemic lupus erythematosus (SLE) is an autoimmune disease mainly affecting the 
connective tissue that consequently demonstrating a plethora of systemic effects mostly 
observed in individuals of African-Asian origin. A staggering 9:1 ratio females to males is 
noted with a peak age of onset in young woman between 25 and 35 years of age. More than 
98% of SLE patients are positive for the antinuclear auto-antibody (ANA), a marker of the 
disease. Other auto-antibodies are used to better refine the diagnosis of SLE and include anti 
cytoplasmic and anti DNA antibodies. The pathology shows a diverse range of symptoms 
affecting several organs ranging from common cutaneous lesions, serous membrane 
alteration and intermittent joints debilitations. More precisely, facial malar rashes, 
arthralagia, polyathritis, pleurisy, pericarditis are experienced along with other symptoms 
like Raynand’s phenomenon and fever. The etiology of this complex disease is unknown but 
several hypotheses have been raised.  Cellular release of antigens from apoptotic and 
necrotic cells is raised that will trigger macrophage phagocytosis and subsequent antigen 
presentation, under MHC class II, of such autoantigens to both T and B-cells. Intracellular 
and extracellular signaling are thought to be dysregulated such as the so called  interferon 
signature, a cytokine profile under scrutiny as links with IRF5 has been shown to be 
associated with SLE (Graham et al., 2006). CD19 positive B-cells are of high attention in 
research as several auto-antibodies are pathogenic in the disease such as the anti nuclear 
antibodies (Madaio et al., 2003). 
The genetics of SLE has pinpointed several chromosomal loci with interestingly the 1q23-24 
region also called the pentraxin locus, a region harboring some key candidates including the 
CRP4 allele gene and the PDCD1 gene. A single nucleotide polymorphism in the PDCD1 
gene was found to disrupt an intronic enhancer that prevents the gene from further 
activation with subsequent apoptotic process alterations. Other hypotheses have been 
investigated such as the possible occupational exposure or environmental effects but with 
no direct significant links to the disease. An interesting phenomenon though is well 
documented with the attention on precipitating factors. Such precipitating factors seen in 
SLE are the intake of oral estrogen contraceptives and hormonal replacement therapies 
(HRT) (Sanchez-Guerrero et al., 1997). Several studies including a nurse health study for 
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oral contraceptive use have shown an increase of 1.9 time SLE manifestations compared to 
non users (Sanchez-Guerrero et al., 1995) and similar effect have been demonstrated with 
HRT (Cooper et al., 2002). In addition a lot of evidence is showing that the SLE 
manifestations are correlated with ovarian cycle alterations (Shabanova et al., 2008). A clear 
link is seen between hormonal changes and SLE therefore higher vigilance is sought for SLE 
women willing to become pregnant.  
2.1.2 Modulation effects of pregnancy in SLE mothers 
Pregnancy presents as a life experience where mother’s hormonal levels are evolutionally 
and physiologically adapting to host the baby. Careful monitoring is undertaken as different 
gestational outcome scenarios are observed, with some being unpredictable, due to 
recurrence of flares and possible life threatening issues affecting both the mother and the 
child. Such dangers ranges from intra-uterine growth retardations in 30% of cases (Meyer 
Oliver, 2003), preterm birth with 25-30% of cases to miscarriages and foetal death. Co-
morbidity is most likely to be observed in SLE patients with increase manifestation of the 
disease in the third trimester of gestation. Lots of evidence show detrimental effects to the 
kidney such as lupus nephritis, and atheroslcerotic pathophysiological establishments 
(Roman et al., 2003 and Asanuma et al., 2003) all to which can be further aggravated with 
other common pregnancy experienced problems like seen with preeclampsia occurrence. 
Death of the mother can be observed with common SLE risks due to high elevations of 
pulmonary hypertension. In 37% of SLE pregnant patients, mild increased of pulmonary 
arterial hypertension can be seen (Johnson et al., 2004).  Such monitoring requires the use of 
several tests, serum antibodies, choice of specific medication, compliance with 
hydroxychloroquine, as well as the monitoring of SLE disease activity index (SLEDAI) 
measuring the flaring panel observed in SLE patients. Interestingly, SLE patients would 
have positive benefits and gains to start their gestation in period of remission before 
conception. An otherwise preconception with active disease otherwise shows increased 
flares with particularly renal disease associated problems (Moroni et al., 2002). In addition, 
lower birth weigths and high number of caesarian deliveries are encountered in proliferative 
nephritis cohorts. Foetal loss in SLE is a major problem with several studies attempting to 
link this fatal outcome to molecular triggering factors. The Hughes syndrome is a 
phospholipid induced pregnancy syndrome commonly named the antiphospholipid 
syndrome. Such syndrome is part of the coagulopathy diseases and SLE pregnant women 
are commonly tested for the presence of lupus anticoagulant factor, an anti phospholipid 
factor named anti-cardiolipin. This immunoglobulin G anti-cardiolipin antibody targets the 
apoprotein H or beta 2 glycoprotein 1. Such antibody prevents the glycoprotein from 
undertaking its possible known function as an inhibitor of the intrinsic coagulation cascade, 
an inhibition required and mediated by the release of complement molecules, C3 and C5 
from the liver. As a consequence, SLE mothers with increase anti-ApoH denote a 
procoagulant pattern with detrimental foetal loss as an outcome. Interestingly, with 
treatment regimens of aspirin and heparin intakes, levels of live birth rates from SLE 
pregnant patients is now around 80% (Clark et al., 2007 and Girardi et al., 2004). Several 
markers for the disease have been found to better classify and understand the pathological 
course. 
Efforts of the research community have helped in the discovery of a series of serum markers 
for SLE such as adipokine, a cell to cell signaling protein secreted by the adipose tissue (De 
Sanctis et al., 2009), CD40L or CD154 found in T-cell surface (De Sanctis et al., 2009 b) and 
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the poly-reactive immunoglobulin M from B-cells (Zhang et al., 2009). All these markers 
denote an intense cell to cell communication and intense modulatory involvement of the 
immune system. Both arms of the immunity system are involved in SLE and particular 
attentions are drawn to further unravel the pathophysiological mechanism in SLE patient’s 
immunity. SLE immune dysregulation involves a role to T-cell activation (Fernandez et al., 
2009), B-cell signaling (Liu et al., 2009 and Peng, 2009) along with altered chemokine 
patterns (Youinou et al., 2009 and Wittmann et al., 2009) with IL-6 playing a role in 
polyarthritis and joint damage (Fonseca et al., 2009) and as mentioned previously an 
interferon signature (Finke et al., 2009).  
The complex cascade of T-cell activation from the T-cell receptor (TCR) the consequently 
increase in intracellular content of Ca2++ and NFAT mediated IL-2 Transcriptional 
activation is an important immune component in SLE. In SLE, such pathway of activation is 
altered and seems to be associated with the calcium processing. ER calcium content not 
being an issue, a lot of attention was given to CRAC and studies have shown altered 
efficiency in this Ca2+ channel. Evidence has also shown that in SLE patients a Ca+ 
alteration was observed and linked to an upstream mitochondrial dysregulation. Evidence 
of high membrane hyperpolarisation (MHP) of the inner membrane of the mitochondrial 
has been pinpointed in SLE T-cells with subsequent ATP decreasing synthesis and failure to 
regenerate glutathione reduced forms, a anti oxidant molecule.   Such dysregulation seems 
to be as well the cause of the unbalance fate observed in SLE T-cells deaths. Instead of 
progressing to a program cell death, with the common FAS pathway and death inducing 
signaling complex cascade, SLE T-cells instead enter necrosis. As both ATP and reduced 
glutathione pools are low, apoptosis is prevented and as such unbalance of quality cell 
death tends to develop into two main consequences. First, necrosis is favored and induces 
inflammation whereas apoptotic bodies do not. Secondly, in SLE, such overall dysregulation 
of calcium (katsiari et al., 2002), ATP formation (Perl et al., 2004) and low antioxidant 
capacity profile (Wang et al., 2010) is in favor to auto-reactive T-cells. 
A strong correlation has been found between CXCL10 and SLE disease (Kong et al., 2009). 
CXCL10 is the interferon inducible factor, chemokine (C-X-C motif) ligand 10 also known as 
IP10 that acts on the receptor CXCR3. Interestingly, the gene coding for such receptor is the 
unique chemokine receptor found in chromosome X. This is in clear contrast to all other 
chemokine receptor genes, suggesting unique functions for CXCR3 and the ligand CXCL10 
in possibly the role in SLE immunity. In sites of inflammation, a subset of B-cells with high 
expression of the marker CD19, a co-receptor of the B-cell receptor and known to be 
implicated in auto-immuniy, shows elevated CXCR3 levels (Nicholas et al., 2007). More 
challenges are met during pregnancy where placental tissues and the new born semi-
allogenic foetal cells are brought together along with SLE (Doria et al., 2008).  High 
consequences were recently tabulated in pregnant women with SLE with approximately 
25% of women presenting with disease exacerbations (Lockshin et al., 1989).  
2.2 Myasthenia and pregnancy 
2.2.1 Pathophysiology of myasthenia gravis 
Besides T-cells, breakdown of self tolerance in autoimmune diseases can be associated with 
humoral B-cell mediated immunity producing pathological auto-antibodies contributing to 
tissue damage as seen in myasthenia gravis (MG). MG is an autoimmune disease affecting 
predominantly women with clinical muscle fatigability with patients suffering from degrees 
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of weakness at various body systems.  Under approximately 40 years of age, women are 
prevalent but after 50 years of age, incidence is then lesser in women than men. (Grob et al., 
2008).  The disease is categorised into two clinical presentations with on one hand, the 
ocular MG affecting of the levator and extra ocular palpebrae skeletal muscles with common 
diplopia and ptosis and in the other hand, generalised MG affecting other skeletal muscles. 
Interestingly, the disease can occur as relapsing remitting and the onset of symptomatology 
is varying from acute to subacute. Auto-antibodies target different antigens including the 
acetylcholine receptor (AchR) and, in most intense disease presentation, target the muscle 
specific muscle protein named MuSK (Padua et al., 2006). AchR and MusK seropositivity 
lead to neuromuscular dysfunctions. In the case of anti AChR, the antibodies trigger 
neutralisation of AChR function (Drachman et al., 1982), as well as antibody dependent 
complement activation with membrane attack complex formation (Engel et al., 1987) and 
finally antibody cross link with the ACHR  leading to the destruction of AChR. The early 
onset MG is also associated with the possible occurrence of other autoimmune insults most 
commonly against the thyroid (Christensen, 1995). In early onset MG, the thymus gland is 
enlarged and patients present with multiple auto-antibodies. However, late onset MG is not 
associated with enlarged thymus. Association of HLA markers with individual type of MG 
onset has been undertaken and data showed that the early onset MG is associated with 
HLA-B8 and DR3 (Compston et al., 1980) whereas late onset MG is associated with HLA B7 
and DR2 (Maggi et al., 1991). Immunologically the thymus is a primary lymphoid organ 
with a highly responsible function to maturate T-cells. T-cells that were produced in the 
bone marrow enter the thymus to become thymocytes to undergo a subsequent series of 
selection. The whole thymus is built to this process with a well vascularised content, clusters 
of different types of cells including antigen presenting cells such as macrophages, dendritic 
cells and parenchymal epithelial cells. When maturation of thymocytes is terminated, an 
efferent drainage successfully drains these cells into mediastinal lymph nodes. This selection 
is aiming at positively selecting immature T-cells which T-cell receptor would recognise 
MHC molecules. In the other hand, the negative selection aims at discarding the T-cells that 
would react to autoantigens presented by APCs. A failure in undertaking the removal of 
autoimmune T-cells is thought to be the problem occurring in MG disease. Certain T-cells, 
Th4 or CD4 + were investigated for their possible cell mediated autoimmune 
dysregulations. Interestingly though, both patients and free of disease normal individuals 
do have autoimmune T-cells targeting AChR (Schluep et al., 1987).  Using experimental 
autoimmune myasthenia gravis (EAMG) animal models with Th1 deficient cells, 
researchers have shown actually that such animals have susceptibility to autoimmunity 
(Balasa et al., 1997). In this latter study, the focus was to distinguish between wild type and 
EAMG interferon gamma knockout mice. Result showed that EAMG knockout mice had no 
weakness to their muscles and were resistance to MG. However, the level of proliferation of 
AChR primed lymph nodes was still proliferating as normally observed in wild type mice.   
As interferon gamma is the primary pro-inflammatory stimulator of TH1 cells with 
downstream activation of the T-bet transcription factor inducing further interferon gamma 
transcription, MG autoimmunity induced solely with Th1 cannot be explaining the entire 
course of the disease. Even other types of autoimmunity such as in multiple sclerosis 
experimental allergic encephalomyelitis animals, observation of both interferon gamma 
deficient mice and T-bet knockout mice did not protect these autoimmunity disorders 
(Ferber et al., 1996). In Balasa et al. study, lymphogenic changes using mice with intact 
thymus were investigated but researchers focus is also turned into directly thymectomized 
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animals. The thymic tissue is also harboring regulatory T-cells CD4+ CD25+ cells or Tregs 
that are anergic to antigen presentation (Crispin et al., 2003). These cells act as suppressors 
of effective autoimmune T-cells as demonstrated in Tregs deficient animal studies showing 
increase signs of autoimmunity disorders (Sakaguchi et al., 1995). Particular markers on the 
surface of Tregs are responsible for the immunological self tolerance function of Treg and 
include CD80, CD28, CD40 and CTLA4 with the later being a strong negative regulator of T-
cell activity. Other subsets of cells called CD4+ CD25+ CD103+ are showing furthermore 
potentials in self tolerance and suppressive functional features in comparison to CD4+ 
CD25+ T-cells.  
2.2.2 Modulation effects of pregnancy in Myasthenia gravis mothers 
T-cells detain estrogen receptors on their membrane and studies have shown a high 
correlation between estrogens and disease detrimental activity. Interestingly, estrogens 
induce an expansion of specific Th1 effector cells with subsequent MG autoimmunity and 
increase of anti AChR antibodies (Delpy et al., 2005).  In normal pregnancy, Tregs mediate 
immune tolerance (Guerin et al., 2009) and data previous data show that in early pregnancy 
estrogens do act on these CD4+ CD25+ T-cells to mediate indeed immunosuppression and 
higher immune tolerance. Such effect is relayed by progesterone during the rest of the 
gestation (Mao et al., 2010). Such positive effect might resign in the difference between 
CD4+ CD25+ and CD4+ CD25- T-cells. Differential gene expression of these two subsets 
showed higher expression levels of CTLA4, galactin, CD103, TNFRSF18, TNFRSF4 and the 
glucocorticoid induced TNF receptor called GITR (McHugh et al., 2002) in CD4+ CD25+ 
cells. Interestingly, inhibition of GITR abrogates regulatory T-cell activity precipitating 
autoimmunity. In addition, GITR can be activated by progesterone receptor (Nelson et al., 
1999 and Kanamaru et al., 2004) and possibly progesterone acts on Treg cells by 
upregulating GITR among other effects. Interestingly, in studies experimenting EAMG 
animals, the treatment of analogs of myasthenogenic peptides notably demonstrated a 
decrease in lymph node proliferation as well as a decrease of INFγ involving the action of 
CD8+ Tregs (Ben-David et al., 2007).  
Newborn can develop neonatal MG and is observed in around 10 % of mother holding the 
burden of the disease (Beekman etal., 1997). This acquisition is mediated by the passage 
from the mother to the foetus of immunoglobulin G anti acetylcholine receptors. In large 
majority, babies do not pursue the course of neonatal MG and few weeks following their 
birth, neonatal MG naturally undergo full resolution. 
2.3 Rheumatoid arthritis and pregnancy 
2.3.1 Pathophysiology of rheumatoid arthritis  
Rheumatoid arthritis is a severe chronic inflammatory disease of relatively high prevalence 
that primarily affects the joints via a systemic autoimmune reaction. While its aetiology 
remains unknown, many cell populations contribute to the inflammatory response in the 
synovium, leading to joint erosions, joint deformation and loss of function.    Histological 
features often include proliferation of synovial cells, plasma and lymphoid cell infiltration, 
neovascularisation, macrophage accumulation and typical palisading structure of the cell 
lining hyperblasting synovial membranes. One particular hallmark used in diagnosis of RA 
is the rheumatoid factor (RF) and the particular association with HLA-DR4. Common 
cytokine abnormalities in RA include an increase in tumor necrosis factor alpha (TNFα) and 
interleukin-1β (IL-1β) with subsequent induction of metalloproteinases (MMPs) degrading 
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the synovial matrix (Dayer et al., 2001).  Gene expression studies sampling synovial tissue 
have highlighted the heterogeneous nature of the disease and suggest the existence and 
contribution of multiple pathogenic pathways (van der Pouw Kraan et al. 2003).  As tissue 
biopsies are invasive, alternative and clinically more practical studies of gene expression 
changes in peripheral blood mononuclear cells (PBMC) from patients with RA have been 
reported (Olsen et al., 2004 & Edwards et al., 2007), with a recent study highlighting that 10 
differentially regulated transcripts in RA patient PBMC mapped to chromosome region 
6p21.3, the major histocompatibility (MHC) locus III (Edwards et al., 2007). In addition to 
the cellular involvement, Rheumatoid arthritis is an auto-antibody disorder that will 
ultimately affect the joints. Antibodies like IgM and IgA are known to target the Fc 
fragments of IgG but in addition targeted citrullinated antigens are found in RA patients but 
are not exclusive to these patients.  The autoimmune attack mainly is associated with 
elevated amounts of Tumor necrosis factor (Feldmann et al., 1996) and elevation of specific 
joint cells (found in both cartilage and synovium). The synovium contains macrophage like 
synovial cells and fibroblast like synovial cells. In RA, the joint macrophage like cells are 
known to secrete a large panel of pro-inflammatory cytokines whereas the fibroblast like 
cells are showing invasive the cartilage (Muller-Ladner et al., 1996) and are responsible, at 
some extent, to joint destruction with osteoclastic activity (Tolboom et al., 2005). 
Interestingly, inhibiting and preventing osteoclast induce destruction of the joints is not 
associated cessation of the overall localised pro-inflammatory profile (Cohen et al., 2008). 
Common therapeutic agents used in treating RA include disease-modifying anti-rheumatic 
drugs (DMARDs), such as methotrexate, non steroidal anti-inflammatory drugs (NSAIDs), 
corticosteroids and Tumor Necrosis Factor (TNF) inhibitors which inhibit the pro-
inflammatory activity of TNF, identified as a key mediator in the inflammatory response. 
Despite the improvement of joint function in 60-80% of patients with TNF inhibitors and 
methotrexate combination therapy, a remaining 20-40% of patients do not respond to this 
treatment (Baton et al., 2000 & Keystone et al., 2004 & Maini et al., 2004). 
2.3.2 Modulation effects of pregnancy in Rheumatoid Arthritis mothers 
In pregnancy, RA signs are improved in more than 76% of cases (Pope et al., 1983) but 
beneficial signs disappear postpartum for approximately 6 to 8 months post delivery. These 
gestational ameliorations seem to be independent of cortisol rises in pregnancy and 
independent to administration of different exogenous estrogen levels (Van den Brink et al., 
1992). Of note, twenty five percent of RA pregnant women have continuing active arthritis. 
Interestingly two reports reported that pregnancy decreases by two fold in RA when 
compared to nulliparous RA women (Spector et al., 1990 & Hazes et al., 1990). During 
pregnancy, important tolerance occurs in RA. Auto-reactive B cells in RA are somewhat 
down-regulated since serum levels of alloantibodies remain the same while improvement in 
the severity is observed (Elenkov et al., 1997). Autoantibodies such as ANA have been 
reported to decrease in RA pregnancy (Ostensen et al., 1983) as well as the rheumatoic 
factor, RF (Pope et al., 1983). Interstingly, the disparity between the foetus and the mother 
seems to be positive for the pregnancy course in RA (Nelson et al, 1993). The impact of the 
disease on pregnancy and outcomes of RA to gestation seem to show no adverse effects with 
RA women falling pregnant and giving birth with no life threatening consequences. 
However, postpartum flares are high and possibly aggravated due to high correlated levels 
of prolactin postpartum (Zrour et al., 2010). The influence of pregnancy on RA disease is still 
unknown and no explannations to date are given for the reasons for observing either 
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remission or none of  RA during pregnancy. As for the remissions, attention is dedicated to 
the maternofetal HLA incompatibility but investigations is generating contrasting reports 
(Brennan et al., 2000). As for what is possibly occuring in RA and pregancy, a hormonal 
conditioning mediated by estradiol and progesterone contribute to a  shift from TH1 to Th2 
immune profile (Ekerfelt et al., 1997) and suppression of both autoreactive T cells and NK 
cells (Otensen & Villiger, 2002). 
2.4 Multiple Sclerosis and pregnancy 
2.4.1 Pathophysiology of Multiple Sclerosis 
MS is a neurological debilitating disorder that affects particularly Caucasians in their second 
to fourth decades of their life (Weinshenker BG, 1998). MS was characterised for the first 
time, by Dr Jean Martin Charcot in 1868 from the hospital “Salpêtrière”, in Paris who 
reported the presence of multiple plaques in the central nervous system (CNS) of a deceased 
patient. Despite the progress of research in the last 150 years the aetiology of MS remains 
still unknown.  
The disorder is well documented for its neuroinflammatory course and symptoms. The 
disease has particular hallmarks and is more prevalent in women, and symptoms appear 
typically between 20 and 40 years of age (Weinshenker BG, 1998). Females account for 
approximately 60% of MS cases (Weinshenker BG et al., 1994). There are several forms of 
MS, characterised by the degree of symptomatic debilitation over time: Benign MS (B-MS), 
Relapsing Remitting MS (RR-MS), Secondary Progressive (SP-MS), Progressive-Relapsing 
MS (PR-MS), Primary Progressive MS (PP-MS). MS plaques appear as lesions in the normal 
white matter (NWM) and occasionally in the gray matter (Peterson et al., 2001). Lesions are 
restricted to the CNS and are not present in the peripheral nervous system (PNS). Plaques 
are classified into three main types: acute (A), chronic active (CA) and chronic silent (CS) MS 
lesions. Acute MS lesions are not well-demarcated (oedematous) and are filled with 
macrophages commonly containing myelin debris. Additionally, these lesions contain 
hypertrophic astrocytes but no fibrous astrogliosis with an abundance of demyelinated 
axons. This plaque-type is characterised by the presence of perivascular lymphocytic 
infiltration and damaged of the blood brain barrier (BBB) (Gay et al., 1991).  Chronic active 
MS lesions, are the second type and do contain a well-demarcated margin. In this case the 
centre of the plaque is lacking in lymphocyte activity. Instead macrophages reside in a 
margin which contains the debris of myelin degeneration. These macrophages are microglia 
in origin. The centre of a CA plaque is astrogliotic, with a generally absence of myelin. 
However, in this case the centre of CA lesions is characterised by signs of remyelination.  
In contrast to both CA and A lesions, CS MS lesions have a highly demarcated margin with 
a fibrous centre with no inflammatory component. Remyelination can occur in the centre 
and within the margin. These plaques appear circular and differ from other forms of 
demyelination (eg. Balo’s syndrome). Balo’s syndrome, is characterised by alternate rings of 
degeneration and regeneration (or intact myelin)(Moore et al., 1985). MS also has an 
autoimmune component, characterised by infiltration in the CNS of activated T-cells that are 
auto-reactive to myelin white matter proteins. MS is also more prevalent at higher latitudes 
of the globe (Hernan et al., 1999), suggesting a strong environmental influence; while 
disease susceptibility has a strong genetic link, as evidenced by numerous twin studies 
(Mumford et al., 1994). Symptoms include limb weakness, sensory loss, visual alterations 
and bladder dysfunction, and the appearance of lesions or plaques that are disseminated in 
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time and space. Multiple sclerosis is an autoimmune disease of the central nervous system, 
characterized by zones of demyelination and inflammatory plaques.   
The genetic of MS has been extensively researched and a major focus in comparison to other 
autoimmune diseases. Studies appreciating the concordance of twins have shown a six time 
increase in risk in monozygoting than among dizogotic twins (Sadovnick et al, 1993).  
2.4.1.1 The Major Histocompatibility Complex (MHC) and Multiple Sclerosis 
The MHC Locus on Chromosome 6p has been linked to the pathogenenesis of MS with the 
fundamental basis of this association being established as a strong association with HLA-
DRB1*15 of the class II gene HLA-DRB1(Fogdell et al., 1995). In addition to the problem in 
exploring possible etiological reasons behind MS, epistatic interaction across alleles are 
taking place that even  are mors of a risky as seen with HLA-DRB1*08, on interaction with 
HLA-DRB1*15. A number of genes have been implicated in MS pathophysiology and were 
discovered throughout both immunological and genetic studies. One of the most consistent 
findings has been an association of specific major histocompatibility class II haplotypes in 
MS (Kellar-Wood et al., 1995). The MHC region in 6p21.3, includes MHC I, II and III. As all 
evidences are supporting an autoimmune basis for MS, the MHC locus is the focus of a lot of 
research attention as the genes in this locus are involved in antigen presentation. Class I and 
class II are involved in antigen presentation to CD8 and CD4 lymphocytes respectively. 
Class I has a region containing HLA loci (HLA A, B, C, E, F, G) known to be altered in 
normal pregnancy especially at the placental border between the foetus and the mother. 
Association between MS and molecules on the chromosome 6p21 is variable to the type of 
population studied. Northern European populations affected with MS do show an 
association with Class II DR15 and DQ6 phenotypes in (Hillert, 1994).  In the other hand, 
Asians with MS are associated with DPB1 (Ito et al., 1998).  
The MHC Class II locus is composed of genes coding for proteins LMP2 (proteasome 
subunit, beta type, 9) and LMP7 (proteasome subunit, beta type, 7), two protein being 
integrative of the proteasome complex. Normally, viral proteins or cellular proteins are 
turned into small peptides by the proteasome. These fragmented petides are then entering 
the reticulum endoplasmic (RE) binding with new synthesised MHC class I molecules. Both 
molecules are then deposited to the surface cell where the peptide is then presented to 
vigilant immune cells. The translocation into the RE is facilitated by the transporter 1, ATP-
binding cassette (TAP) 1 and 2 which are coded by genes in the MHC Class II region. 
Studies attempted to demonstrate a probable association between TAP1 and TAP2 locus 
polymorphisms but data showed no association with MS (Vandevyver et al., 1994). 
However, the same study revealed though a differential level of gene expression of these 
two genes between affected and non-affected tissues. Interestingly, a lot of attention was 
brought into a region 100kb telomeric to HLA F. This locus harbors the myelin 
oligodendrocyte glycoprotein (MOG), another potential candidate gene in multiple sclerosis 
as it plays an important role in myelin sheath maintenance and immunogenicity. 
Experiments using antisera raised against MOG would activate a downstream signaling 
pathway resulting in the degradation of microtubules and disruption of myelin basic 
protein (MBP) (Johns et al., 1999). This pathway is also triggered by antibodies of a marker 
of myelin-producing cells, the galactolipid galactocerebroside, that was illustrated in glioma 
cells (Joshi et al., 1992), with possibly engaging a second messenger (most likely Inositol 
Phosphate 3) activating a voltage Ca2+
 
channel (Joshi et al., 1998) that ultimately results into 
in an increase of intracellular calcium and microtubule disruption.  
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In the Class III MHC region, candidate genes possibly implicated in MS pathology include 
the steroid enzyme 21-hydroxylase gene (CYP21A2) and heat shock proteins (HSP): HSP70-1 
and HSP70-2. In addition, MHC class III region contains genes coding for complement 
molecules of the immune system and interestingly the tumour necrosis factor genes (TNFα 
and TNFβ). In Multiple sclerosis, TNFα has been shown to be toxic to oligodendrocytes and 
myelin (Wingerchuk et al., 1997). In MS plaques, TNFβ is present and is at the origin of 
tissue repair (De Groot et al., 1999). Some studies have investigated TNFα polymorphisms 
(Wingerchuk et al., 1997) however no association was found with MS except in HLA-DR2+ 
MS patients compared with HLA-DR2- individuals (Oturai et al., 1999). Studies 
investigating Caucasians of European descent have shown that class II HLA alleles are more 
strongly associated with the HLA-DR2 haplotype in MS (Haines et al., 1998).  
Noteworthy a predominant immunological hallmark of multiple sclerosis is the important 
clonal expansion of class I MHC T8 lymphocytes observed in MS (Gay et al., 1997).   
2.4.1.2 Immunological mechanism involved in MS 
The immune system response is comprised of two immune systems: humoral and cellular. 
In the case of MS, both systems apply resulting in CNS inflammation coupled with 
degeneration in myelin sheath. A plethora of cells may be involved in this disorder 
including microglial cells (macrophages of the CNS), B and T lymphocytes, natural killer 
cells and peripheral macrophages (Li et al., 1993). Their activities are coupled with the 
secretion of activating signals such as cytokines and interleukines that upon production 
affect surrounding cells. It has been reported that auto-reactive T-cells exist in the peripheral 
blood from both MS affected and healthy individuals (Lindert et al., 1999). In order to reach 
the CNS, the immune cells have to cross through the BBB but only activated T-cells can 
penetrate this fence. However, it has been reported that in MS the BBB undergoes a 
breakdown resulting in facilitated passage of immune cells (McDonald et al., 1992). The 
activation of T-cells is supposed to be due to a misguided immune response secondary to 
cross recognition of epitopes shared between a microbial pathogen and a putative antigen in 
the CNS (Wucherpfennig et al., 1995). These CNS-antigen specific T-cells transmigrate 
through the endothelial BBB by secreting and expressing adhesion molecules such as 
selectins and integrins (Monteyne et al., 1997). The T-cells occupy the CNS in regions where 
further events take place. Furthermore, once they have occupied the CNS, the T-cells 
stimulate the entry of further immune cells such as peripheral macrophages. Passage of 
macrophages in the CNS is facilitated by the T-cell induced BBB disruption due to secretion 
of activated matrix metalloproteases (MMPs). In the cerebrospinal fluid of MS patients, a 
high gelatinase (MMP9) concentration has been found (Rosenberg et al., 1996). Gelatinase B 
breaks down the BBB and its inhibition, by serine protease inhibitors, shows a protective 
effect on the MS animal model, EAE Lewis rats (Brosnan et al., 1980). In the parenchymal of 
the CNS, T-cells are reactivated with the myelin antigen proximity and secrete a vast group 
of pro-inflammatory agents such as interferon gamma (INFγ), tumour necrosing factor alpha 
and beta (TNFα and TNFβ), interleukin 2 (IL-2) (Olsson et al., 1995). IL-2 is an autocrine 
interleukin triggering a T-cell auto-activation loop process. On both astrocytes and microglial 
cells, those inflammatory mediators trigger an up-regulation of MHC class II molecules. The 
increase of MHC class II molecules at the surface of these cells improves the amount of antigen 
presenting cells. Moreover, microglia as well as T lymphocytes are developing a proliferating 
process in response of INFγ action (Martino et al., 1995 & Grau et al., 1997). Interestingly, T-bet 
knockout mice show resistance to autoimmunity (Bettelli et al., 2004). 
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Activated astrocytes trigger an up-regulation of adhesion molecules at the surface of the 
BBB (Weiss et al., 1998). Chemo-attractants are produced such as the monocyte chemo-
attractant protein 1 (MCP-1) (Van Der Voon et al., 1999) that chemically orientate peripheral 
phagocytes towards the BBB. The BBB endothelium is thus facilitated for further influx of 
inflammatory cells such as macrophages. Even macrophages disrupt the BBB with the 
secretion of neurotoxins (Brosnan et al., 1981). Secondly, activated astrocytes are able to 
excrete more pro-inflammatory molecules that turn the local CNS microglia (CNS resident 
macrophages) into ameboid microglia, a more active macrophage state. The activated 
astrocytes excrete factors such as GM-CSF (granulocyte monocyte-colony stimulating factor) 
whose role is to induce the proliferation of the ameboid cells.  
The local microglia plays an important role in local antigen presentation in the CNS of EAE 
animals (Bauer et al., 1994) allowing an immune response. The microglia is expressing B7 
(Dangond et al., 1997) and vascular cell adhesion molecule (VCAM-1). These two molecules 
bind CD28 and the very late antigen 4 (VLA4) respectively, on the surface of T-cells (Chabot 
et al., 1997) and these molecular interactions affect T-cell activation. Complement receptors 
(CR1 and CR2) are also found and are molecules that allow the binding of complement 
coated targets to phagocytosis. Complement activation constitutes the major component 
mechanism of humoral immunity. Contact with complement permits a better activation of 
the microglia but also the release of TNFα and interleukins (IL-1 and IL-6) (Rajan et al., 
1996). Microglia express receptors for Fc fragments of immunoglobulins (Ulvestad et al., 
1994) and completes an association action with B-lymphocytes. Those B-lymphocytes, fewer 
in numbers, can pass the damaged BBB and produce antibodies against myelin proteins 
(Gerritse et al., 1994). The antibodies are observed, after a lumbo-puncture, in CSF from MS 
patients appearing as oligoclonal bands in agarose gel electrophoresis. T-cell infiltration in 
the CNS not only induces microglial activation but also triggers the recruitment of high 
numbers of macrophages (Hulkower et al., 1993).  
Besides inflammation, demyelination is the second most characteristic feature of MS 
pathology. Both microglia and macrophages are capable of ingesting myelin in EAE animals 
(Rinner et al., 1995). However, oligodendrocytes do not express MHC calls II molecules so 
CD4+T-cells cannot have a direct effect. Studies have shown that both complement and 
immunoglobulins are detected on oligodendrocytes and microglia in MS brain but none of 
the studies have ever shown the complement system alone (Fabry et al., 1994). 
Oligodendrocytes are damaged via antibody cell mediated cytotoxicity (ADCC) triggered by 
microglia, macrophages with the help of T4+, B-cells and complements molecules (Ozawa et 
al., 1994). The macrophages act as APCs via the major histocompatibility molecule class II. 
Their activities are indicators of ongoing demyelination activity (Li et al., 1993). 
Furthermore, the interaction of B-cells with T4 cells (CD40-CD40L) turns the B-lymphocytes 
into APCs, which in consequence increase the myelinotoxic activity. Antibodies to CD 40 
ligand (CD 40L) can prevent the MS like disease in EAE animals (Boon et al., 2001). MBP-
specific CD8+ T-cells are detected in MS plaques and have been shown to be cytotoxic in 
vitro on HLA-A2 not HLA-A3 transfected oligodendrocyte cell lines in the presence of MBP 
peptide 110-118 (Jurewicz et al., 1998).  
2.4.2 Modulation effects of pregnancy in Multiple Sclerosis mothers 
A first and remarkable large prospective study was undertaken to monitor MS and 
pregnancy relation and finally counseling MS pregnant women for their venture into 
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pregnancy (Confavreux et al, 1998). MS disease does not affect the outcome of pregnancy 
and interestingly from the first to the successive trimesters of gestation, a decrease in 
exacerbation rates is observed with at the third trimester a decrease of 87.5% of relapse 
rates (Confavreux et al., 1998). This gestational decrease in symptomatology is directly 
observed with a decrease of MS MRI abnormalities in the CNS in MS pregnant women 
(Van Walderveen et al., 1994). Most interestingly MS patients entering pregnancy even 
show a reduced MS progressive course and severity in comparison to controls 
(Runmarker et al., 1995 & Verdru et al., 1994). No differences in rates of caesarians are 
seen in MS (Mueller et al., 2002). A lot of attention is driven towards obvious gestational 
steroids such as estrogens and progesterone. Previous studies have shown the 
autoimmune protection of estrogens which action decrease TNF-α secretion from 
microglial cells (Dimayuga et al., 2005) and the neurosteroid enhancement effects of 
progesterone on myelin formation (Jung-Testas et al., 1999). Progesterone has been shown 
to act on myelination in the peripheral nervous system with marked remyelination 
following cryo-lesions in mouse sciatic nerves (Koenig et al., 2000). Progesterone acts on 
its receptor, progesterone receptor (PGR), a receptor localized in Chromosome 11q12, a 
locus with denotes slight association in MS susceptibility in Australia (Ban et al, 2003). In 
animals, progesterone shows remarkable actions as a neuro-protector agent (Singh et al., 
2008). Activation of the PR by progesterone exerts immunosuppressive roles by directly 
inhibiting a subunit of NF-κB, a well known intermediate of the pro-inflammatory 
molecule TNF alpha action (Kalkhoven et al., 1996). In addition, it has been demonstrated 
that progesterone exerts a protective role on damage brain tissues (Cutler et al., 2007) 
especially in Traumatic Brain Injuries (TBI) (VanLandingham et al., 2007). 
A very interesting study has been undertaken to assess the immunogenic activity occurring 
in MS pregnancy (Saraste et al., 2007). Natural killer cells and B and T-cells populations with 
both CD4+ and CD8 + T-cells were all assessed during pregnancy in MS with staggering 
results showing a decrease from first to third trimester of nearly 40% of NK count in blood 
of MS patients to then increase by 53% by three months postpartum. In healthy pregnant 
women a same trend of decrease in NK population is observed (Saraste et al., 2007). This 
fluctuation of such important innate immunity cellular component is obviously strongly 
altered by pregnancy and accomplished seen in MS women. Steroids such as progesterone 
were investigated to establish their roles on NK cells and it has been shown that 
progesterone induces apoptosis of mature peripheral blood natural killers CD16+ CD56 dim 
(Arruvito et al., 2008). In Saraste et al. study, an important hallmark demonstrated though a 
grand difference in CD4+/CD8+ ratios in MS pregnant women versus healthy pregnant 
women. In From the first to third trimester, MS pregnant women have a CD4+/CD8+ ratio 
of  1.9 that increase to 2.7 in the third trimester whereas  healthy pregnant women showed 
an inverse trend from 2.4 to 1.6. Authors attempted to give an explanation by seeing such 
trend as either an increase in T regulatory T-cells or the act that T-cells were prevented from 
reaching the CNS in pregnancy. 
In contrary to gestational time, post partum MS condition is associated with an increase of 
relapse rate (Bernardi et al., 1991) to resume back to baseline values approximately three 
months post partum (Roullet et al.,1993). Breast feeding is not affecting the postpartum 
relapse rate frequency and could be encouraged by the physician except if particular drug 
treatments are in use (Nelson et al., 1988). 
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3. Conclusion 
The following review was aimed at understanding the interactive relation of the 
physiological gestational adaptations in coexistence with particular autoimmune diseases. 
Discussion focused on four diseases that include SLE, MS, MG and RA. Such relation is of 
no doubt a very complicating process that progressively starts to unravel.  Thanks to the 
overall international research on both the pathogenic mechanism of autoimmunity and 
enhancement of gestational immunity understanding, new hypothesises and more 
importantly more insights are found.  A powerful physiological protective process occurs in 
pregnancy, a process strong enough to demonstrate decrease symptomatology in MS, RA 
and MG pregnancies. In the other hand, SLE pregnancies do not follow such trend and even 
is showing further aggravation. Mothers are facing a double challenge by undertaking all 
physiological adaptations of their pregnancy and going through these autoimmune 
diseases. Steroid hormones play an important role and attempt to orchestrate the foeto-
maternal immunological cross communication. In addition regulatory T cells are the direct 
biological ‘diplomats’ that taking act on immune-modulating this complex biological 
enigma. 
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